BDBM235821 US9364459, H

SMILES: COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCO)c2ccccc12

InChI Key: InChIKey=AZLMJFCIKMLKAZ-UHFFFAOYSA-N

Data: 3 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 235821   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human))	BDBM235821 (US9364459, H) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCO)c2ccccc12 |t:13| Show InChI InChI=1S/C23H22N2O6/c1-29-17-10-13(11-18(30-2)21(17)31-3)19-20(23(28)24-22(19)27)15-12-25(8-9-26)16-7-5-4-6-14(15)16/h4-7,10-12,26H,8-9H2,1-3H3,(H,24,27,28)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	153	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 beta (Homo sapiens (Human))	BDBM235821 (US9364459, H) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCO)c2ccccc12 |t:13| Show InChI InChI=1S/C23H22N2O6/c1-29-17-10-13(11-18(30-2)21(17)31-3)19-20(23(28)24-22(19)27)15-12-25(8-9-26)16-7-5-4-6-14(15)16/h4-7,10-12,26H,8-9H2,1-3H3,(H,24,27,28)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens (Human))	BDBM235821 (US9364459, H) Show SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCO)c2ccccc12 |t:13| Show InChI InChI=1S/C23H22N2O6/c1-29-17-10-13(11-18(30-2)21(17)31-3)19-20(23(28)24-22(19)27)15-12-25(8-9-26)16-7-5-4-6-14(15)16/h4-7,10-12,26H,8-9H2,1-3H3,(H,24,27,28)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	554	n/a	n/a	n/a	n/a	n/a	n/a
Johannes Gutenberg-Universität Mainz; Universitätsmedizin der Johannes Gutenberg-Universität Mainz US Patent					Assay Description The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...				US Patent US9364459 (2016) BindingDB Entry DOI: 10.7270/Q2ZK5FK2
					More data for this Ligand-Target Pair